Drug Database · Clinicians

Mometasone

Brands (54) Elica, Momate, Zymocort…Show all

US brand (reference label): Mometasone Furoate; not a Philippine-registered brand.

Corticosteroid (nasal preparation); Topical corticosteroid; and others PH FDA category

Rx · Prescription drugOTC · Over-the-counter69 PH products
Dispensing: Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID ff41e901-5a6f-4ad5-be8a-a68eae787e5e, version date August 20, 2022 (Mometasone Furoate · Amneal Pharmaceuticals LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Prophylaxis of Nasal Symptoms of Seasonal Allergic Rhinitis in adult and pediatric patients 12 years of age and older
  • Treatment of Chronic Rhinosinusitis with Nasal Polyps in adult patients 18 years of age and older
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Mometasone furoate nasal spray is a corticosteroid indicated for: Prophylaxis of Nasal Symptoms of Seasonal Allergic Rhinitis in adult and pediatric patients 12 years of age and older (1.1) Treatment of Chronic Rhinosinusitis with Nasal Polyps in adult patients 18 years of age and older (1.2) 1.1 Prophylaxis of Seasonal Allergic Rhinitis Mometasone furoate nasal spray 50 mcg is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years and older. 1.2 Treatment of Chronic Rhinosinusitis with Nasal Polyps Mometasone furoate nasal spray 50 mcg is indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients 18 years of age and older.

Contraindications

4 CONTRAINDICATIONS Mometasone furoate nasal spray is contraindicated in patients with known hypersensitivity to mometasone furoate or any of its ingredients [see Warnings and Precautions (5.3), Description (11)]. Patients with known hypersensitivity to mometasone furoate or any of the ingredients of mometasone furoate nasal spray. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • For Nasal Use Only. Prophylaxis of Seasonal Allergic Rhinitis in Adult and Pediatric Patients 12 Years of Age and Older: 2 sprays in each nostril once daily (2.2)
  • Treatment of Chronic Rhinosinusitis with Nasal Polyps in Adults (18 yrs. and older): 2 sprays in each nostril twice daily. 2 sprays in each nostril once daily may also be effective in some patients (2.3)
2.1 Preparation and Administration

2.1 Preparation and Administration Administer mometasone furoate nasal spray by the nasal route only. Initial Priming Prior to initial use of mometasone furoate nasal spray, the pump must be primed by actuating ten times or until a fine spray appears. The pump may be stored unused for up to 1 week without repriming. Repriming (as needed) If unused for more than 1 week, reprime by actuating two times, or until a fine spray appears.

2.2 Recommended Dosage for Prophylaxis of Seasonal Allergic Rhinitis

2.2 Recommended Dosage for Prophylaxis of Seasonal Allergic Rhinitis The recommended dosage for prophylaxis treatment of nasal symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years and older is mometasone furoate 2 sprays (2 sprays deliver a total of 100 mcg of mometasone furoate) in each nostril once daily (total daily dose of 200 mcg). In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis with 2 sprays (2 sprays deliver a total of 100 mcg of mometasone furoate) in each nostril once daily (total daily dose of 200 mcg) is recommended 2 to 4 weeks prior to the anticipated start of the pollen season.

2.3 Recommended Dosage for Treatment of Chronic Rhinosinusitis with Nasal Polyps

2.3 Recommended Dosage for Treatment of Chronic Rhinosinusitis with Nasal Polyps The recommended dosage for the treatment of chronic rhinosinusitis with nasal polyps in adults 18 years and older is mometasone furoate 2 sprays (2 sprays deliver a total of 100 mcg of mometasone furoate) in each nostril twice daily (total daily dose of 400 mcg). A dose of 2 sprays (2 sprays deliver a total of 100 mcg of mometasone furoate) in each nostril once daily (total daily dose of 200 mcg) is also effective in some patients.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (pharmacokinetics)

Patients with Renal Impairment: The effects of renal impairment on mometasone furoate pharmacokinetics have not been adequately investigated.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Impairment Concentrations of mometasone furoate appear to increase with severity of hepatic impairment [see Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of mometasone furoate nasal spray for prophylaxis of the nasal symptoms of seasonal allergic rhinitis in pediatric patients 12 years of age and older have been established [see Adverse Reactions (6.1) and Clinical Studies (14.1)]. Use of mometasone furoate nasal spray for this indication is supported by evidence from controlled trials in adult and pediatric patients 12 years of age and older [see Clinical Studies (14.1)].

The safety and effectiveness of mometasone furoate nasal spray for the treatment of chronic rhinosinusitis with nasal polyps in pediatric patients less than 18 years of age have not been established. Effectiveness was not demonstrated in one 4-month trial conducted to evaluate the safety and efficacy of mometasone furoate in the treatment of chronic rhinosinusitis with nasal polyps in pediatric patients 6 to 17 years of age.

The primary objective of the study was to evaluate safety; efficacy parameters were collected as secondary endpoints. A total of 127 patients with chronic rhinosinusitis with nasal polyps were randomized to placebo or mometasone furoate nasal spray 100 mcg once or twice daily (patients 6 to 11 years of age) or 200 mcg once or twice daily (patients 12 to 17 years of age).

The results of this trial did not support the efficacy of mometasone furoate nasal spray in the treatment of chronic rhinosinusitis with nasal polyps in pediatric patients. The adverse reactions reported in this trial were similar to the adverse reactions reported in patients 18 years of age and older with chronic rhinosinusitis with nasal polyps.

Effect on Growth Controlled clinical studies have shown nasal corticosteroids may cause a reduction in growth velocity in pediatric patients. This effect has been observed in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function.

The long-term effects of this reduction in growth velocity associated with nasal corticosteroids, including the impact on final adult height, are unknown. The potential for “catch up” growth following discontinuation of treatment with nasal corticosteroids has not been adequately studied. The growth of pediatric patients receiving nasal corticosteroids, including mometasone furoate nasal spray, should be monitored routinely (e.g., via stadiometry).

The potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of safe and effective noncorticosteroid treatment alternatives. To minimize the systemic effects of nasal corticosteroids, including mometasone furoate nasal spray, each patient should be titrated to his/her lowest effective dose.

A clinical study to assess the effect of mometasone furoate nasal spray (100 mcg total daily dose) on growth velocity has been conducted in pediatric patients 3 to 9 years of age with allergic rhinitis. No statistically significant effect on growth velocity was observed for mometasone furoate nasal spray compared to placebo following one year of treatment.

No evidence of clinically relevant HPA axis suppression was observed following a 30-minute cosyntropin infusion. The potential of mometasone furoate nasal spray to cause growth suppression in susceptible patients or when given at higher doses cannot be ruled out.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use A total of 280 patients above 64 years of age with allergic rhinitis or chronic rhinosinusitis with nasal polyps (age range 64 to 86 years) have been treated with mometasone furoate nasal spray for up to 3 or 4 months, respectively. No observed differences in safety and/or effectiveness in geriatric patients compared to younger adult patients.

Administration

2.1 Preparation and Administration Administer mometasone furoate nasal spray by the nasal route only. Initial Priming Prior to initial use of mometasone furoate nasal spray, the pump must be primed by actuating ten times or until a fine spray appears. The pump may be stored unused for up to 1 week without repriming. Repriming (as needed) If unused for more than 1 week, reprime by actuating two times, or until a fine spray appears.

US FDA label

Dosage forms

Philippines

  • Cream: 1 mg per g, 1 mg/g
  • Nasal spray suspension: 50 mcg per actuation, 50 mcg/Actuation, 50 mcg/dose, 500 mcg/mL
  • Topical cream: 1 mg/g, 10 mg/g
  • Ointment: 1 mg/g
  • ) cream: 1 mg/g
  • Aqueous nasal spray: 50 mcg/actuation, 500 mcg/g
  • Nasal spray: 50 mcg, 50 mcg per actuation
  • Lotion: 1 mg/g
  • Metered-dose nasal spray: 50 mcg/actuation
  • Metered dose nasal spray: 50 mcg/spray

and 4 more forms; see the products table.

Registered products in the Philippines

69 products registered with the Food and Drug Administration (FDA) Philippines list Mometasone as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products69
Philippine FDA-registered products for Mometasone
Package insert
BapicremMometasone Furoate
1 mg/g (0.1% w/w) Topical CreamAluminum Tube x 5 g and 15 g (Box of 1's)
Rx
PSA Chemicals & Pharmaceuticals Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.
DRP-16264
Jan 14, 2030
DiametasoneMometasone Furoate
1 mg/g (0.1% w/w) CreamCollapsible Aluminum Tube 15 g (Box of 1’s)
Rx
Agio Pharmaceuticals LimitedIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-2797-04
Oct 10, 2037
ElicaMometasone Furoate
1 mg /g (0.1%) LotionHDPE bottle x 30 mL (Box of 1's)
Rx
Delpharm Montreal Inc.Canada
Importer: Bayer Philippines, Inc.
DR-XY19711
Oct 26, 2029
ElicaMometasone (as Furoate)
1 mg/g OintmentAluminum Tube with PP Cap x 5g (Box of 1's)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Bayer Philippines, Inc.
DR-XY47270
May 11, 2031
ElicaMometasone (as Furoate)
1mg/g CreamAluminum Tube with PP Cap x 5g (Box of 1's)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Bayer Philippines Inc.
DR-XY47268
May 11, 2031
ElicortMometasone furoate
1 mg per g (0.1% w/w) Cream5 g and 10 g Aluminum Collapsible Tube Box of 1’s
Rx
DONGKWANG PHARM. CO., LTDRepublic of Korea
ENDURE MEDICAL, INC.
DR-XY41202
Sep 4, 2027
ElicortMometasone (as furoate)
1 mg/g (0.1%) Ointment10g Aluminum tube (Box of 1's)
Rx
—
Endure Medical, Inc.
DR-XY42264
Jul 29, 2028
Eloate™Mometasone Furoate
1 mg/g (0.1 w/w) CreamAluminum Tube x 5 g (Box of 1's)
Rx
Rhydburg Pharmaceuticals Ltd.India
Pharmastar Int'l Trading Corp.Trader: Sheer Essentials
DRP-17769
Feb 27, 2032
LomeaneMometasone Furoate
1 mg /g (0.1%) CreamAluminum Collapsible Tube X 5 g (Box of 1's)
Rx
Shou Chan Industrial Co., Ltd.Taiwan
New Smart Formulae Trading Corp.
DR-XY41521
Dec 27, 2029
McortphilMometasone Furoate
1 mg/g (0.1% w/w) Topical CreamPrinted Laminated Tube x 10 g (Box of 1's)
OTC
KLM Laboratories Pvt. Ltd.India
Philrx Pharma Inc.
DRP-12443-01
Aug 15, 2027
MeliaMometasone Furoate
1 mg/g (0.1% w/w) CreamCollapsible Aluminum Tube x 15 g (Box of 1’s)
Rx
Agio Pharmaceuticals Ltd.India
Kaufmann Pharma Inc.Importer: Ambica International Corporation
DRP-2797-05
Sep 22, 2037
MelometMometasone Furoate
1 mg/g (0.1% w/w) Topical CreamAluminium Tube x 10 g (Box of 1's)
OTC
Y.S.P. Industries (M) SDN. BHD.Malaysia
Yung Shin (Philippines), Inc.
DR-XY48573
Jan 26, 2028
MetaloMometasone Furoate
1 mg per gram (0.1% w/w) CreamLami Tube x 10 g (Box of 1's)
Rx
Curetech SkincareIndia
Ambica International Corporation
DRP-8953
Aug 6, 2030
Metamist DMMometasone Furoate
50 mcg Nasal Spray15 mL (Net Content: 14 mL) White HDPE Bottle with nasal spray pump, white opaque polypropylene actuator and translucent protection cap x 120 metered doses (Box of 1's)
Rx
Biodeal Pharmaceuticals Limited.India
D&M Pharma Corp.
DR-XY49608
Jan 19, 2031
MetsonMometasone Furoate
1 mg/g (0.1% w/w) Topical CreamAluminum Collapsible Tube x 10 g (Box of 1's)
Rx
Dae Hwa Pharmaceutical Co., Ltd.Republic of Korea
Bellus Life Solutions, Inc.
DRP-8720
Oct 25, 2032
MezoMometasone Furoate
1 mg/g (0.1% w/w) CreamCollapsible Aluminum Tube x 5 g and 15 g (Box of 1’s)
Rx
Agio Pharmaceuticals LimitedIndia
TGP Pharma, Inc.Importer: Ambica International Corporation
DRP-2797
Sep 3, 2031
MfsoneMometasone Furoate
1 mg/g (0.1% w/w) CreamLaminated Tube packed in Printed Monocarton x 10g (Box of 1’s)
Rx
KLM Laboratories Pvt. Ltd.India
FSPC Pharmaceuticals Inc.Importer: AMB HK Enterprises Inc.Trader: KLM Laboratories Pvt. Ltd.
DRP-9012
Aug 3, 2030
MfsoneMometasone Furoate
10 mg/g (0.1% w/w) Topical CreamLaminated Collapsible Tube x 5g and x10 g
OTC
Scott-Edil Pharmacia LimitedIndia
AMB HK Enterprises Inc.
DRP-10935
Dec 20, 2026
MmcortMometasone Furoate
1 mg/g (0.1% w/w) Topical CreamPrinted Laminated Tube x 10g (Box of 1's)
OTC
KLM Laboratories Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-12443
Aug 15, 2027
MmfredMometasone Furoate
1 mg/g (0.1% w/w) Topical CreamLaminated Tube x 10 g and 15 g
OTC
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-11729
Apr 25, 2027
MmfredMometasone Furoate
1 mg/g (0.1% w/w) Topical CreamPrinted Laminated Tube x 10 g (Box of l's); Printed Laminated Tube x 15 g (Box of l's)
OTC
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-12639
Sep 19, 2027
ModexaMometasone Furoate (As Monohydrate)
50 mcg/actuation Nasal Spray SuspensionOpaque metered dose HDPE Plastic bottle with white nasal spray pump and white Polypropylene nasal applicator protected by translucent Polypropylene cap x 140 actuations (Box of 1's)
Rx
FarmeaFrance
Glorious Dexa Mandaya, Inc.Trader: 0
DRP-14026
Jun 6, 2028
MomateMometasone furoate
0.1 % w/w (1mg/g) CreamAluminum Tube x 5 g (Box of 1's); Aluminum Tube x 3 g (Box of 1's) Physician's Sample
Rx
Glenmark Pharmaceuticals Ltd.India
Glenmark Philippines, Inc.
DR-XY29551
Apr 27, 2031
MomateMometasone furoate
0.1% OintmentAluminum Tube x 5g (Box of 1's); Aluminum Tube x 3g [Physician's Sample] (Box of 1's)
Rx
Glenmark Pharmaceuticals Ltd.India
Glenmark Philippines, Inc.
DR-XY30243
Nov 10, 2031
MomateMometasone furoate (as monohydrate)
50 mcg/Actuation Nasal Spray SuspensionWhite Opaque HDPE Bottle Crimped with Nasal Spray Pumps Fitted with Actuator and Cap Bottles of 60 metered dose and 120 metered dose (Box of 1's)
Rx
Glenmark Pharmaceuticals Ltd.India
Glenmark Philippines, Inc.
DR-XY45503
Jul 14, 2031
MomeclirMometasone Furoate
500 mcg/mL Nasal Spray SuspensionWhite Opaque PE Bottle with Spray Pump and Actuator Sealed with White PE Shoulder and Closed with Dark Green PP Cap x 18 mL (Box of 1's)
Rx
Hanlim Pharmaceutical Co., Ltd.Republic of Korea
OEP Philippines, Inc.Importer: H & B Pharma International Inc.
DRP-8845-01
May 9, 2031
MomecortMometasone Furoate
1 mg/g (0.1%) Lotion30 mL Oval LDPE Bottle with LDPE Plug and PP Screw-On-Cap (Box of 1's)
Rx
Asian Antibiotics, Inc.Philippines
Trader: Unilab, Inc.
DR-XY35881
May 22, 2029
MomefloMometasone Furoate
1 mg/g (0.1% w/w) CreamAluminum Tube x 10 g (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Transcend Phils., Inc.
DRP-10018
Jul 15, 2030
MomefloMometasone Furoate
1 mg/g (0.1%) OintmentCollapsible Aluminum Tube x 10 g Box of 1's
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Transcend Phils., Inc.
DRP-8957
Aug 19, 2031
MomegardMometasone Furoate
1 mg/g (0.1% w/w) CreamAluminum Collapsible Tube with White HDPE Cap x 10 g (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Foramen Products Corporation
DRP-8723
Jan 29, 2031
MomegenMometasone Furoate
1 mg/g (0.1% w/w) CreamCollapsible Aluminum Tube x 10 g Box of 1's
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DR-XY39975
Aug 31, 2031
MomenaseMometasone furoate (as monohydrate)
50 mcg/dose Nasal Spray Suspension20 mL-Capacity White opaque HDPE plastic bottle x 140 doses with HDPE pump and cap (Box of 1's)
Rx
Synmosa Biopharma Corporation (Synmosa Plant)Taiwan
Synmosa Biopharma Philippines Inc.
DRP-17446
Jun 18, 2031
MomenexMometasone furoate (as monohydrate)
50 mcg/actuation Aqueous Nasal SprayHDPE bottle x 20 mL with HDPE pump and cap. (Box of 1's)
Rx
Synmosa Biopharma Corporation (Synmosa Plant)Taiwan
Endure Medical Inc.
DR-XY48691
Apr 5, 2028
MomeproMometasone Furoate
1 mg/g (0.1% w/w) Cream10 g Alimunum Collapsible Tube with White HDPE Cap (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DR-XY44527
Feb 15, 2031
MomerightMometasone Furoate
50 mcg per actuation Nasal SprayUSP Type I Amber Glass Vial with White Actuator and Spray Pump X 15 mL (Box of 1's)
Rx
Norris Medicines LimitedIndia
I.E. Medica, Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-6632-01
Apr 22, 2029
MomesoneMometasone
0.1% w/w (1 mg/g) CreamAluminum Collapsible Tube x 5 g and 15 g (Box of 1's)
Rx
The Government Pharmaceutical OragnizationThailand
Importer: Exa Life Care Pharma Inc.
DRP-14819
Apr 30, 2029
MometarexMometasone Furoate
1mg/g (0.1%w/w) CreamAluminium Collapsible Tube x 5 g, 10 g, 15 g, 20 g, and 30 g (Box of 1's)
OTC
Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China
Aarex Pharma Distributor
DRP-12627
Sep 16, 2027
MometasaphMometasone Furoate
1 mg/g CreamAluminum Collapsible Tube x 5 g, 10 g, 15 g, 20 g, and 30 g (Box of 1's)
Rx
Azine Healthcare Pvt. Ltd.India
Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd
DRP-9375
Dec 15, 2030
MometasaphMometasone Furoate
1mg/g (0.1%w/w) Topical CreamLaminated plastic tube x 5g, 10g, 15g, 20g and 30g (Box of 1’s)
Rx
Sai Parenterals Ltd.India
Nelpa Lifesciences, IncImporter: Nelpa Lifesciences, Inc.
DRP-18057
Apr 30, 2031
MometixMometasone Furoate (As monohydrate)
50 mcg/actuation (0.05% w/w) Metered-Dose Nasal Spray26 mL-HPDE bottle with metered-dose spray pump, se spray nasal actuator and cap x 140 actuations (Box of 1's)
Rx
Drogsan Ilaclari Sanayi ve Ticaret A.Ş.Turkey
Orange Biotec Inc.
DRP-12065
Jun 6, 2027
MometrexMometasone Furoate(As Monohydrate)
50 mcg/ Actuation (0.05 % w/v) Nasal Spray SuspensionWhite HDPE Bottle with Metered Dose Pump Actuator Sealed with Dust Cap x 15 mL (Box of 1's)
Rx
Biodeal Pharmaceuticals Pvt. LtdIndia
Medinova Pharmaceutical Inc.
DRP-18209
May 28, 2031
MomevexMometasone Furoate
1mg/g 0.1% w/w CreamLaminated Tube x 5 g 15 g (Box of 1's)
OTC
Yash PharmaceuticalsIndia
VE Pharm Inc.Trader: Vexxa Lifesciences Pvt, Ltd.
DR-XY48749
May 26, 2028
MomezelMometasone Furoate
1 mg/g (0.1% w/w) CreamCollapsible aluminum tube with white PET screw cap (Box of 1's)
Rx
Front Pharmaceutical PLCChina
AMB HK Enterprises Inc.
DRP-17429
Jan 20, 2031
MosasprayMometasone Furoate (as monohydrate)
50 mcg/actuation Nasal Spray SuspensionHDPE Bottle with Nasal Spray Pump x 120 and 140 actuations (Box of 1's)
Rx
Lek Pharmaceuticals D.D.Slovenia
Importer: Sandoz Philippines Corporation
DRP-6145
May 13, 2030
NasativeMometasone Furoate
500 mcg/mL Nasal Spray SuspensionWhite Opaque PE Bottle with Spray Pump and Actuator Sealed with White PE Shoulder and Closed with Dark Green PP Cap x 18 mL (Box of 1's)
Rx
Hanlim Pharmaceutical Co., Ltd.Republic of Korea
H & B Pharma International Inc.
DRP-8845
Dec 1, 2031
NasehalerMometasone furoate (as monohydrate)
50 mcg per actuation (0.05% w/w) Nasal Spray Suspension20 mL White Opaque HDPE vial with nasal metered pump and nasal actuator x 140 actuation (Box of 1's)
Rx
Cipla Limited, Indore Sez (Unit III)India
RV Group Phil. Branch
DRP-13925
May 18, 2028
NasocareMometasone Furoate (as Monohydrate)
50 mcg per actuation Suspension for Nasal SprayOpaque Metered Dose High Density Polyethylene Plastic Bottle with White Nasal Spray Pump, Plastic Safety Clip and Dust Cap x 20 mL (Net Content) (Box of 1's)
Rx
World Medicine İlaç Sanayi Ve Ticaret A.Ş.Turkey
Pharma-Surrey International, Inc.
DRP-8316
Aug 13, 2029
NasomateMometasone furoate (as monohydrate)
50 mcg/actuation Nasal Spray Suspension18.5 mL in 20mL White HDPE Bottle with spray pump actuator (Box of 1's)
Rx
Samchundang Pharm. Co., Ltd.Korea
I-Senz Medical Inc.
DR-XY45599
Sep 20, 2031
NasonexMometasone Furoate (as monohydrate)
500 mcg/g Aqueous Nasal SprayHDPE Bottle (140 metered actuation) x 18 g (Box of 1's); HDPE Bottle (60 metered actuation) x 10 g (Box of 1's); HDPE Bottle (40 metered actuation) x 10 g as Physician's Sample (Box of 1's)
Rx
Schering-Plough Labo NVBelgium
Importer: Organon (Philippines) Incorporated
DRP-4855
Nov 11, 2028
NasopremMometasone furoate (as monohydrate)
50 mcg/actuation (0.05% w/w) Metered-Dose Nasal Spray26 mL-HDPE bottle with metered-dose spray pump, nasal actuator and cap x 140 actuations (Box of 1's)
Rx
Drogsan Ilaclari Sanayi ve Ticaret A.S.Turkey
Premier Pharmaceuticals Marketing Corp.Importer: Orange Biotec Inc.
DRP-12065-01
Jun 6, 2027
NomasonMometasone Furoate
1 mg/g (0.1% w/w) Topical CreamAluminum Collapsible Tube x 10 g (Box of 1's)
OTC
Dae Hwa Pharmaceutical Co., Ltd.Republic of Korea
Best Remedy Medicines Pharmaceutical Co.Importer: Bellus Life Solutions, Inc.
DRP-8720-01
Oct 25, 2027
NoneMometasone Furoate
1 mg/g (0.1 % w/w) Cream15-g Aluminum Collapsible Tube with White Cap (Box of 1's)
Rx
U SQUARE LIFESCIENCES PVT.LTD.India
Importer: SKINGEN BIOTECH, INC.
DR-XY42689
Mar 15, 2028
NovacortMometasone Furoate (as monohydrate)
500 mcg/g Aqueous Nasal SprayPlastic Bottle (140 Sprays) with a Metered-Dose Manual Spray Pump x 18 g (Box of 1's)
Rx
Yuhan CorporationKorea
Medinova Pharmaceutical Inc.
DRP-15649
Aug 14, 2029
NovatasoneMometasone Furoate
1 mg/g (0.1% w/w) Topical CreamLami Tube x 10 g (Box of 1's)
OTC
Blossom PharmaceuticalsIndia
Medinova Pharmaceutical Inc.
DRP-10870
Dec 9, 2026
RinoeaseMometasone furoate (as monohydrate)
50 mcg/ actuation (0.05% w/w) Nasal Spray Suspension.White Opaque HDPE Bottle with PP Spray Pump Sealed with Cap x 60 metered-actuations (Box of 1's)
Rx
ICPA Health Products LimitedIndia
Preventia Healthcare, Inc.
DRP-14201
Jul 18, 2028
RizmocrimMometasone Furoate
1 mg/g (0.1% w/w) CreamCollapsible Aluminum Tube x 10 g (Box of 1's)
Rx
Lloyd Laboratories, Inc.Bulacan
Trader: Euro-Health Care Exponents, Inc.
DRP-8956
Nov 14, 2031
RynorexMometasone furoate
50 mcg/spray Metered Dose Nasal SprayHDPE bottle fitted with a metered valve x 25 mL (Box of 1's)
Rx
Square Pharmaceuticals LimitedBangladesh
UNILAB, Inc.
DR-XY43055
Dec 5, 2028
SagamomeMometasone Furoate
1 mg/g (0.1 w/w%) Topical CreamLami Tube x 15 g (Box of 1's)
Rx
Yash Medicare Private LimitedIndia
Penta Labs Australia (PhilippinesTrader: U Square Lifescience Pvt. Ltd.
DRP-16389
Feb 26, 2030
SkatoMometasone Furoate
1 mg/g (0.1% w/ w) CreamAluminum Collapsible Tube x 10g (Box of 1's)
OTC
Rhydburg Pharmaceuticals LimitedIndia
Genedrift Philippines OPC
DRP-16330
Feb 6, 2030
SprasoneMometasone furoate
0.1% w/w (1 mg/g) CreamLaminated Tube x 5 g and 15 g (Box of 1's)
Rx
PSA Chemicals & Pharmaceuticals Pvt. Ltd.,India
Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd.
DRP-159400
Jul 9, 2029
UnbrandedMometasone Furoate
1 mg/g (0.1% w/w) CreamCollapsible Aluminum Tube x 5 g and 15 g (Box of 1’s)
Rx
Agio Pharmaceuticals LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-2797-02
Oct 10, 2037
UnbrandedMometasone Furoate
1 mg/g (0.1% w/w) CreamCollapsible Aluminum Tube x 5 g and 15 g (Box of 1’s)
Rx
Agio Pharmaceuticals LimitedIndia
Ritemed Phils., Inc.Importer: Ambica International Corporation
DRP-2797-03
Sep 22, 2037
United Home DermatecMometasone (as Furoate)
1 mg/g (0.1% w/w) OintmentAluminum Collapsible Tube with Plastic Screw Cap x 5 g (Box of 1's)
OTC
Asian Antibiotics, Inc.Philippines
Unilab, Inc.
DRP-2051
May 25, 2029
United Home DermatecMometasone (as Furoate)
1 mg/g (0.1%) CreamAluminum Collapsible Tube with Plastic Screw Cap x 5 g (Box of 1's)
Rx
Asian Antibiotics, Inc.Philippines
Trader: UNILAB, Inc.
DRP-2035
May 25, 2029
WelicaMometasone Furoate
1 mg/g (0.1% w/w) CreamAluminum Collapsible Tube x 5 g, 10 g, 15 g, 20 g, and 30 g (Box of 1’s)
Rx
Mascot Health Series Pvt. Ltd.India
Importer: Wellchem Pharmaceutical Products
DRP-9651
Apr 20, 2031
ZymocortMometasone Furoate
50 mcg per actuation Nasal SprayUSP Type I Amber glass vial with white actuator and spray pump x 15 mL (Box of 1's)
Rx
Norris Medicines LimitedIndia
Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-6632
Apr 22, 2029
ZymocortMometasone furoate (as monohydrate)
50 mcg/actuation Nasal Spray SuspensionHDPE Bottle with Nasal Spray Pump x 120 Actuations (Box of 1's)
Rx
Lek Pharmaceuticals D.D.Slovenia
The Cathay Drug Co., Inc.Importer: Sandoz Philippines Corporation
DRP-6145-01
Mar 2, 2031
ZymocortMometasone Furoate
500 mcg/mL Nasal Spray SuspensionWhite Opaque PE Bottle with Spray Pump and Actuator Sealed with White PE Shoulder and Closed with Dark Green PP Cap x 18 mL (Box of 1's)
Rx
Hanlim Pharmaceutical Co., Ltd.Republic of Korea
The Cathay Drug Co., Inc.Importer: H & B Pharma International Inc.
DRP-8845-02
May 6, 2031
ZynovateMometasone furoate
1 mg/g (0.1% w/w) CreamCollapsible Aluminum Tube x 15 g (Box of 1's)
Rx
Oman Pharmaceutical Products Co., L.L.C.Oman
Atlantic Pharmaceuticals, Inc.
DR-XY44036
Jan 7, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Nasal spray: 50 mcg of mometasone furoate in each spray. Nasal spray: 50 mcg of mometasone furoate, USP in each spray (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Epistaxis, nasal ulceration, Candida albicans infection, nasal septal perforation, impaired wound healing. Monitor patients periodically for signs of adverse effects on the nasal mucosa. Avoid use in patients with recent nasal ulcers, nasal surgery, or nasal trauma. (5.1)
  • Glaucoma and cataracts. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use mometasone furoate nasal spray long term. (5.2)
  • Potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. More serious or even fatal course of chickenpox or measles in susceptible patients. Use caution in patients with the above because of the potential for worsening of these infections. (5.4)
  • Hypercorticism and adrenal suppression with higher than recommended dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue mometasone furoate nasal spray slowly. (5.5)
  • Potential reduction in growth velocity in children. Monitor growth routinely in pediatric patients receiving mometasone furoate nasal spray. (5.6, 8.4)
5.1 Local Nasal Adverse Reactions Epistaxis

5.1 Local Nasal Adverse Reactions Epistaxis Epistaxis was observed more frequently in patients with allergic rhinitis and patients with chronic rhinosinusitis with nasal polyps who received mometasone furoate nasal spray than those who received placebo [see Adverse Reactions (6.1)]. Candida Infection Localized infections of the nose and pharynx with Candida albicans has occurred from nasal administration of mometasone furoate.

When such an infection develops, use of mometasone furoate nasal spray should be discontinued and appropriate local or systemic therapy instituted, if needed. Nasal Septum Perforation Instances of nasal septum perforation occurred in patients following the nasal application of corticosteroids, including mometasone furoate.

As with any long-term topical treatment of the nasal cavity, patients using mometasone furoate nasal spray over several months or longer should be examined periodically for possible changes in the nasal mucosa. Impaired Wound Healing Because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal septum ulcers, nasal surgery, or nasal trauma should not use a nasal corticosteroid until healing has occurred.

5.2 Glaucoma and Cataracts

5.2 Glaucoma and Cataracts Glaucoma and cataracts may be reported with systemic and topical (including nasal, inhaled and ophthalmic) corticosteroid use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use mometasone furoate long term [see Adverse Reactions (6)].

5.3 Hypersensitivity Reactions

5.3 Hypersensitivity Reactions Hypersensitivity reactions including instances of wheezing may occur after the nasal administration of mometasone furoate. Discontinue mometasone furoate nasal spray if such reactions occur [see Contraindications (4)].

5.4 Immunosuppression and Risk of Infections

5.4 Immunosuppression and Risk of Infections Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chickenpox and measles, for example, can have a more serious or even fatal course in nonimmune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure.

How the dose, route, and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated.

If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective Prescribing Information for VZIG and IG.) If chickenpox develops, treatment with antiviral agents may be considered. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculous infection of the respiratory tract, or in untreated fungal, bacterial, systemic viral infections, or ocular herpes simplex because of the potential for worsening of these infections.

5.5 Hypercorticism and Adrenal Suppression

5.5 Hypercorticism and Adrenal Suppression Hypercorticism and adrenal suppression may occur when nasal corticosteroids, including mometasone furoate, are used at higher-than-recommended dosages [see Dosage and Administration (2)] or in patients at risk for such effects. If such changes occur, the dosage of mometasone furoate nasal spray should be discontinued slowly, consistent with accepted procedures for discontinuing oral corticosteroid therapy.

5.6 Effect on Growth

5.6 Effect on Growth Corticosteroids, including mometasone furoate, may cause a reduction in growth velocity when administered to pediatric patients. Routinely, monitor the growth of pediatric patients receiving mometasone furoate nasal spray. To minimize the systemic effects of nasal corticosteroids, including mometasone furoate nasal spray, titrate each patient’s dose to the lowest dosage that effectively controls his/her symptoms [see Use in Specific Populations (8.4)].

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS No formal drug-drug interaction studies have been conducted with mometasone furoate nasal spray. Inhibitors of Cytochrome P450 3A4: Studies have shown that mometasone furoate is primarily and extensively metabolized in the liver of all species investigated and undergoes extensive metabolism to multiple metabolites.

In vitro studies have confirmed the primary role of cytochrome CYP3A4 in the metabolism of this compound. Concomitant administration of CYP3A4 inhibitors may inhibit the metabolism of, and increase the systemic exposure to, mometasone furoate and potentially increase the risk for systemic corticosteroid side effects. Caution should be exercised when considering the co-administration of mometasone furoate nasal spray with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Clinical Pharmacology (12.3)].

Consider the benefit of co-administration versus the potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side effects.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4 (CYP3A4).

In vitro studies have confirmed the primary role of cytochrome CYP3A4 in the metabolism of this compound.

Concomitant administration of CYP3A4 inhibitors may inhibit the metabolism of, and increase the systemic exposure to, mometasone furoate and potentially increase the risk for systemic corticosteroid side effects.

Caution should be exercised when considering the co-administration of mometasone furoate nasal spray with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Clinical Pharmacology (12.3) ] .

Adverse reactions

Adverse reactions (US label) US FDA label

The following clinically significant adverse reactions are described elsewhere in labeling: Epistaxis, Ulcerations, Candida albicans Infection, Impaired Wound Healing [see Warnings and Precautions (5.1)] Glaucoma and Cataracts [see Warnings and Precautions (5.2)] Immunosuppression and Risk of Infections [see Warnings and Precautions (5.4)] Hypercorticism and Adrenal Suppression, including Growth Reduction [see Warnings and Precautions (5.5, 5.6), Use in Specific Populations (8.4)] The most common adverse reactions (incidence ≥ 5%) included headache, viral infection, pharyngitis, epistaxis and cough. (6) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Allergic Rhinitis Adults and pediatric patients 12 years of age and older In controlled U.S. and international clinical studies, a total of 3,210 adult and pediatric patients 12 years and older with allergic rhinitis received treatment with mometasone furoate nasal spray at doses of 50 mcg/day to 800 mcg/day.

The majority of patients (n = 2,103) were treated with 200 mcg/day. A total of 350 adult and pediatric patients 12 years and older have been treated for one year or longer. Adverse reactions did not differ significantly based on age, sex, or race. Four percent or less of patients in clinical trials discontinued treatment because of adverse events and the discontinuation rate was similar for the vehicle and active comparators.

All adverse reactions (regardless of relationship to treatment) reported by 5% or more of adult and pediatric patients ages 12 years and older who received mometasone furoate nasal spray, 200 mcg/day vs. placebo and that were more common with mometasone furoate nasal spray than placebo, are displayed in Table 1 below. Table 1: Adult and Pediatric Patients 12 Years and Older – Adverse Reactions from Controlled Clinical Trials in Seasonal Allergic and Perennial Allergic Rhinitis (Percent of Patients Reporting) MOMETASONE FUROATE 200 mcg (n=2103) % VEHICLE PLACEBO (n=1671) % Headache 26 22 Viral Infection 14 11 Pharyngitis 12 10 Epistaxis/Blood-Tinged Mucus 11 6 Coughing 7 6 Upper Respiratory Tract Infection 6 2 Dysmenorrhea 5 3 Musculoskeletal Pain 5 3 Sinusitis 5 3 Other adverse reactions which occurred in less than 5% but greater than or equal to 2% of adult and pediatric patients (ages 12 years and older) treated with mometasone furoate nasal spray, 200-mcg/day (regardless of relationship to treatment), and more frequently than in the placebo group included: arthralgia, asthma, bronchitis, chest pain, conjunctivitis, diarrhea, dyspepsia, earache, flu-like symptoms, myalgia, nausea, and rhinitis.

Chronic Rhinosinusitis with Nasal Polyps Adults 18 years of age and older In controlled clinical studies, the types of adverse reactions observed in patients with chronic rhinosinusitis with nasal polyps were similar to those observed in patients with allergic rhinitis. A total of 594 adult patients (ages 18 to 86 years) received mometasone furoate nasal spray at doses of 200 mcg once or twice daily for up to 4 months for treatment of chronic rhinosinusitis with nasal polyps.

The overall incidence of adverse reactions for patients treated with mometasone furoate nasal spray was comparable to patients with the placebo except for epistaxis, which was 9% for 200 mcg once daily, 13% for 200 mcg twice daily, and 5% for the placebo. Nasal ulcers and nasal and oral candidiasis were also reported in patients treated with mometasone furoate nasal spray primarily in patients treated for longer than 4 weeks.

6.2 Post-Marketing Experience

6.2 Post-Marketing Experience The following adverse reactions have been identified during the post-marketing period for mometasone furoate nasal spray: nasal burning and irritation, anaphylaxis and angioedema, disturbances in taste and smell, nasal septal perforation, and vision blurred. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Adverse reaction frequency tables (US label) US FDA label
MOMETASONE FUROATE 200 mcg (n=2103) % VEHICLE PLACEBO (n=1671) %
Headache 26 22
Viral Infection 14 11
Pharyngitis 12 10
Epistaxis/Blood-Tinged Mucus 11 6
Coughing 7 6
Upper Respiratory Tract Infection 6 2
Dysmenorrhea 5 3
Musculoskeletal Pain 5 3
Sinusitis 5 3

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Mometasone is minimally absorbed systemically following nasal use, and maternal use is not expected to result in fetal exposure to the drug. Available data from observational studies of mometasone use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.

In animal reproduction studies with pregnant mice, rats, or rabbits (subcutaneous, subcutaneous/topical dermal/oral, and topical dermal/oral, respectively), mometasone furoate caused increased fetal malformations and decreased fetal survival and growth following administration of doses that produced exposures approximately 1/3 to 8 times the maximum recommended human dose (MRHD) on a mcg/m 2 or AUC basis [see Data]. However, experience with oral corticosteroids suggests that rodents are more prone to teratogenic effects from corticosteroid exposure than humans.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data Animal Data In an embryofetal development study with pregnant mice dosed throughout the period of organogenesis, mometasone furoate produced cleft palate at a dose less than the maximum recommended daily intranasal dose (MRDID) (on a mcg/m 2 basis with maternal subcutaneous doses of 60 mcg/kg and above) and decreased fetal survival at approximately 2 times the MRDID (on a mcg/m 2 basis with a maternal subcutaneous dose of 180 mcg/kg). No toxicity was observed with a dose that produced an exposure less than the MRDID (on a mcg/m 2 basis with maternal topical dermal doses of 20 mcg/kg and above).

In an embryofetal development study with pregnant rats dosed throughout the period of organogenesis, mometasone furoate produced fetal umbilical hernia at exposures approximately 10 times the MRDID (on a mcg/m 2 basis with maternal topical dermal doses of 600 mcg/kg and above) and delays in fetal ossification at a dose approximately 6 times the MRDID (on a mcg/m 2 basis with maternal topical dermal doses of 300 mcg/kg and above). In another reproductive toxicity study, pregnant rats were dosed with mometasone furoate throughout pregnancy or late in gestation.

Treated animals had prolonged and difficult labor, fewer live births, lower birth weight, and reduced early pup survival at a dose less than the MRDID (on a mcg/m 2 basis with a maternal subcutaneous dose of 15 mcg/kg). There were no findings at a dose less than the MRDID (on a mcg/m 2 basis with a maternal subcutaneous dose of 7.5 mcg/kg).

Embryofetal development studies were conducted with pregnant rabbits dosed with mometasone furoate by either the topical dermal route or oral route throughout the period of organogenesis. In the study using the topical dermal route, mometasone furoate caused multiple malformations in fetuses (e.g., flexed front paws, gallbladder agenesis, umbilical hernia, hydrocephaly) at doses approximately 6 times the MRDID (on a mcg/m 2 basis with maternal topical dermal doses of 150 mcg/kg and above).

In the study using the oral route, mometasone furoate caused increased fetal resorptions and cleft palate and/or head malformations (hydrocephaly and domed head) at a dose approximately 30 times of the MRDID (on a mcg/m 2 basis with a maternal oral dose of 700 mcg/kg). At approximately 110 times the MRDID (on a mcg/m 2 basis with a maternal oral dose of 2800 mcg/kg), most litters were aborted or resorbed.

No effects were observed at a dose approximately 6 times the MRDID (on a mcg/m 2 basis with a maternal oral dose of 140 mcg/kg).

Breastfeeding considerations

Lactation (US label) US FDA label

8.2 Lactation Risk Summary There are no available data on the presence of mometasone furoate nasal spray in human milk, the effects on the breastfed child, or the effects on milk production. However, mometasone is minimally absorbed systemically by the mother following nasal use, and breastfeeding is not expected to result in exposure of the infant to mometasone.

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for mometasone furoate nasal spray and any potential adverse effects on the breastfed infant from mometasone furoate nasal spray or from the underlying maternal condition.

Mechanism of action

12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.

In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins.

The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells).

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Adrenal Function in Adults: Four clinical pharmacology studies have been conducted in humans to assess the effect of mometasone furoate nasal spray at various doses on adrenal function. In one study, daily doses of 200 and 400 mcg of mometasone furoate nasal spray and 10 mg of prednisone were compared to placebo in 64 patients (22 to 44 years of age) with allergic rhinitis.

Adrenal function before and after 36 consecutive days of treatment was assessed by measuring plasma cortisol levels following a 6-hour Cortrosyn (ACTH) infusion and by measuring 24-hour urinary free cortisol levels. Mometasone furoate nasal spray, at both the 200- and 400-mcg dose, was not associated with a statistically significant decrease in mean plasma cortisol levels post-Cortrosyn infusion or a statistically significant decrease in the 24-hour urinary free cortisol levels compared to placebo.

A statistically significant decrease in the mean plasma cortisol levels post-Cortrosyn infusion and 24-hour urinary free cortisol levels was detected in the prednisone treatment group compared to placebo. A second study assessed adrenal response to mometasone furoate nasal spray (400 and 1,600 mcg/day), prednisone (10 mg/day), and placebo, administered for 29 days in 48 male volunteers (21 to 40 years of age).

The 24-hour plasma cortisol area under the curve (AUC 0-24), during and after an 8-hour Cortrosyn infusion and 24-hour urinary free cortisol levels were determined at baseline and after 29 days of treatment. No statistically significant differences in adrenal function were observed with mometasone furoate nasal spray compared to placebo.

A third study evaluated single, rising doses of mometasone furoate nasal spray (1,000, 2,000, and 4,000 mcg/day), orally administered mometasone furoate (2,000, 4,000, and 8,000 mcg/day), orally administered dexamethasone (200, 400, and 800 mcg/day), and placebo (administered at the end of each series of doses) in 24 male volunteers (22 to 39 years of age). Dose administrations were separated by at least 72 hours.

Determination of serial plasma cortisol levels at 8 AM and for the 24-hour period following each treatment were used to calculate the plasma cortisol area under the curve (AUC 0-24). In addition, 24-hour urinary free cortisol levels were collected prior to initial treatment administration and during the period immediately following each dose.

No statistically significant decreases in the plasma cortisol AUC, 8 AM cortisol levels, or 24-hour urinary free cortisol levels were observed in volunteers treated with either mometasone furoate nasal spray or oral mometasone, as compared with placebo treatment. Conversely, nearly all volunteers treated with the three doses of dexamethasone demonstrated abnormal 8 AM cortisol levels (defined as a cortisol level <10 mcg/dL), reduced 24-hour plasma AUC values, and decreased 24-hour urinary free cortisol levels, as compared to placebo treatment.

In a fourth study, adrenal function was assessed in 213 patients (18 to 81 years of age) with chronic rhinosinusitis with nasal polyps before and after 4 months of treatment with either mometasone furoate nasal spray, (200 mcg once or twice daily) or placebo by measuring 24-hour urinary free cortisol levels. Mometasone furoate nasal spray, at both doses (200 and 400 mcg/day), was not associated with statistically significant decreases in the 24-hour urinary free cortisol levels compared to placebo.

Three clinical pharmacology studies have been conducted in pediatric patients to assess the effect of mometasone furoate nasal spray on the adrenal function at daily doses of 50, 100, and 200 mcg vs. placebo. In one study, adrenal function before and after 7 consecutive days of treatment was assessed in 48 pediatric patients with allergic rhinitis (ages 6 to 11 years) by measuring morning plasma cortisol and 24-hour urinary free cortisol levels.

Mometasone furoate nasal spray, at all three doses, was not associated with a statistically significant decrease in mean plasma cortisol levels or a statistically significant decrease in the 24-hour urinary free cortisol levels compared to placebo. In the second study, adrenal function before and after 14 consecutive days of treatment was assessed in 48 pediatric patients (ages 3 to 5 years) with allergic rhinitis by measuring plasma cortisol levels following a 30-minute Cortrosyn infusion.

Mometasone furoate nasal spray, 50 mcg, at all three doses (50, 100, and 200 mcg/day), was not associated with a statistically significant decrease in mean plasma cortisol levels post-Cortrosyn infusion compared to placebo. All patients had a normal response to Cortrosyn. In the third study, adrenal function before and after up to 42 consecutive days of once-daily treatment was assessed in 52 patients with allergic rhinitis (ages 2 to 5 years), 28 of whom received mometasone furoate nasal spray, 50 mcg per nostril (total daily dose 100 mcg), by measuring morning plasma cortisol and 24-hour urinary free cortisol levels.

Mometasone furoate nasal spray was not associated with a statistically significant decrease in mean plasma cortisol levels or a statistically significant decrease in the 24-hour urinary free cortisol levels compared to placebo.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination: Following intravenous administration, the effective plasma elimination half-life of mometasone furoate is 5.8 hours.

Any absorbed drug is excreted as metabolites mostly via the bile, and to a limited extent, into the urine.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption: Mometasone furoate administered as a nasal spray suspension has very low bioavailability (<1%) in plasma using a sensitive assay with a lower quantitation limit (LOQ) of 0.25 pcg/mL. Distribution: The in vitro protein binding for mometasone furoate was reported to be 98% to 99% in concentration range of 5 ng/mL to 500 ng/mL.

Elimination: Following intravenous administration, the effective plasma elimination half-life of mometasone furoate is 5.8 hours. Any absorbed drug is excreted as metabolites mostly via the bile, and to a limited extent, into the urine. Metabolism: Studies have shown that any portion of a mometasone furoate dose which is swallowed and absorbed undergoes extensive metabolism to multiple metabolites.

There are no major metabolites detectable in plasma. Upon in vitro incubation, one of the minor metabolites formed is 6ß-hydroxy-mometasone furoate. In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4 (CYP3A4). Specific Populations: Patients with Hepatic Impairment: Administration of a single inhaled dose of 400 mcg mometasone furoate to subjects with mild (n = 4), moderate (n = 4), and severe (n = 4) hepatic impairment resulted in only 1 or 2 subjects in each group having detectable peak plasma concentrations of mometasone furoate (ranging from 50 to 105 pcg/mL).

The observed peak plasma concentrations appear to increase with severity of hepatic impairment, however, the numbers of detectable levels were few. Patients with Renal Impairment: The effects of renal impairment on mometasone furoate pharmacokinetics have not been adequately investigated. Pediatric Patients: Mometasone furoate pharmacokinetics have not been investigated in the pediatric population [see Use in Specific Populations (8.4)].

Male and Female Patients: The effects of gender on mometasone furoate pharmacokinetics have not been adequately investigated. Racial or Ethnic Groups: The effects of race on mometasone furoate pharmacokinetics have not been adequately investigated. Drug Interaction Studies: Inhibitors of Cytochrome P450 3A4: In a drug interaction study, an inhaled dose of mometasone furoate 400 mcg was given to 24 healthy subjects twice daily for 9 days and ketoconazole 200 mg (as well as placebo) were given twice daily concomitantly on Days 4 to 9.

Mometasone furoate plasma concentrations were <150 pcg/mL on Day 3 prior to co-administration of ketoconazole or placebo. Following concomitant administration of ketoconazole, 4 out of 12 subjects in the ketoconazole treatment group (n=12) had peak plasma concentrations of mometasone furoate >200 pcg/mL on Day 9 (211 to 324 pcg/mL).

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Mometasone Furoate · Amneal Pharmaceuticals LLC [US FDA-approved label, version 15, August 20, 2022]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff41e901-5a6f-4ad5-be8a-a68eae787e5e
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .